How is Wee1 Inhibition Utilized in Cancer Therapy?
Wee1 inhibitors, such as AZD1775 (also known as adavosertib), are being explored in clinical trials for their potential to selectively kill cancer cells. These inhibitors can be particularly effective in tumors with p53 mutations, where the G1 checkpoint is compromised, making cancer cells more dependent on the G2/M checkpoint. By using Wee1 inhibitors, the therapeutic strategy is to exploit this dependency, pushing cells into mitosis before they are ready, resulting in mitotic catastrophe.
